Health-related quality of life assessment in multiple sclerosis

Reviews in Neurological Diseases

Volumn 5, Issue 2, 2008, Pages 56-64

  Miller, Deborah M ^a   Kinkel, R Philip ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Clinical care; Health related quality of life; Multiple sclerosis; Patient care; Patient reported outcomes

Indexed keywords

CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; HEALTH STATUS; HUMAN; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; QUALITY OF LIFE; REVIEW;

HEALTH STATUS; HUMANS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE;

EID: 46749135636     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Sackette DL. Evidence-Based Medicine: How to Practice and Teach EBM. New York: Churchill Livingston; 1997.
2. Schipper H, Clinch JJ, Olweny CLM. Quality of life studies: definitions and conceptual issues. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996:11-23.
3. The Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee. Multiple Sclerosis Quality of Life Inventory: A User's Manual. New York: National Multiple Sclerosis Society; 1997.
4. Guyatt G, Jaeschke R, Feeny DH, Patrick L. Measurements in clinical trials: choosing the right approach. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996:41-47.
5. Rothwell PM. Quality of life in multiple sclerosis [comment|. J Neurol Neurosurg Psychiatry. 1998;65:433.
6. Guarnaccia JB, Aslan M, O'Connor TZ, et al. Quality of life for veterans with multiple sclerosis on disease-modifying agents: relationship to disability. J Rehahil Res Dev. 2006;43:35-44.
7. Freeman JA, Langdon DW, Hobart JC, Thompson AJ. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology. 1999;52:50-56.
8. Greenhalgh J, Long AE, Flynn R. The use of patient reported outcome measures in routine clinical practice: lack of impact or lack of theory? Soc Sci Med. 2005;60:833-843.
9. Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial.[see comment] [erratum appears in JAMA. 2003;289:987]. JAMA. 2002;288:3027-3034.
10. Wright EP, Selby PJ, Crawford M, et al. Feasibility and compliance of automated measurement of quality of life in oncology practice. J Clin Oncol. 2003;21:374-382.
11. Carone DA, Benedict RHB, Munschauer FE 3rd, et al. Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. J Int Neuropsychol Soc. 2005;11:574-583.
12. Vickrey BG. Getting oriented to patient-oriented outcomes [comment]. Neurology. 1999;53:662-663.
13. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study. Mult Scler. 2002;8:330-338.
14. Jones JB, Snyder CE, Wu AW. Issues in the design of Internet-based systems for collecting patient-reported outcomes. Qual Life Res. 2007;16:1407-1417.
15. Frost MH, Bonomi AE, Cappelleri JC, et al. Applying quality-of-life data formally and systematically into clinical practice. Mayo Clin Proc. 2007;82:1214-1228.
16. Brundage M, Feldman-Stewart D, Leis A, et al. Communicating quality of life information to cancer patients: a study of six presentation formats. J Clin Oncol. 2005;23:6949-6956.
17. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622-629.
18. Kaplan RM, Anderson JP, Spilker B. The general heath policy model: an integrated approach. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996:309-322.
19. Kattan MW. Comparing treatment outcomes using utility assessment for health-related quality of life. Oncology. 1997;17:1687-1693.
20. Fisk JD, Brown MG, Sketris IS, et al. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry. 2005;76:58-63.
21. Kolattukudy SJ, Kattan MW, Miller DM, Fox R. Risk tolerance in multiple sclerosis patients. Paper presented at: American Academy of Neurology 2007 Annual Meeting; April 28-May 5, 2007; Boston, MA. Abstract 166.
22. Solari A. Role of health-related quality of life measures in the routine care of people with multiple sclerosis. Health Qual Life Outcomes. 2005;3:16.
23. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler. 2003;9:63-72.
24. Benito-Leon J, Morales JM, Rivera-Navarro J, Mitchell A. A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil. 2003;25:1291-1303.
25. Gruenewald DA, Higginson IJ, Vivat B, et al. Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review. Mult Scler. 2004;10:690-704.
26. Freeman JA, Thompson AJ, Fitzpatrick R, et al. Interferon-Beta1b in the treatment of secondary progressive MS: impact on quality of life. Neurology. 2001;57:1870-1875.
27. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679-687.
28. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
29. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-923.
30. Kappos L, Bates D, Hartung H-P, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 2007;6:431-441.
31. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62:335-346.
32. Confavreux C, Paty DW. Current status of computerization of multiple sclerosis clinical data for research in Europe and North America: the EDMUS/MS-COSTAR connection. European Database for Multiple Sclerosis. Multiple Sclerosis-Computed Stored Ambulatory Record. Neurology. 1995;45:573-576.
33. Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult Scler. 1999;5:293-296.
34. Koch-Henriksen N, Rasmussen S, Stenager E, Madsen M. The Danish Multiple Sclerosis Registry. History, data collection and validity. Dan Med Bull. 2001;48:91-94.
35. Palace J, Boggild M. The UK Multiple Sclerosis database. Mult Scler. 1999;5:297-298.
36. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain. 2004;127:844-850.
37. Minden SL, Frankel D, Hadden L, et al. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler. 2006;12:24-38.
38. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
39. Minden SL, Frankel D, Hadden LS, et al. Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. Neurorehabilitation. 2004;19:55-67.
40. Marrie RA, Cutter G, Tyry T, et al. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology. 2007;68:1971-1978.
41. Hadjimichael O, Kerns RD, Rizzo MA, et al. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain. 2007;127:35-41.
42. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66:1696-1702.
43. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343.
44. Hohol MJ, Orav EJ, Werner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45:251-255.
45. Schwartz CE, Vollmer T, Lee H. Reliability and validity of 2 self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology. 1999;52:63-70.
46. Hohol MJ, Orav EJ, Weiner HL. Disease Steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler. 1999;5:349-354.
47. Marrie RA, Cutter G, Tyry T, et al. Validation of the NARCOMS Registry: pain assessment. Mult Scler. 2005;11:338-342.
48. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Users Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
49. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53-72.
50. Vickrey BG, Hays RD, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 1995;4:187-206.
51. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981;19:787-805.
52. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40-66.
53. Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124:962-973.
54. Schwartz CE, Coulthard-Morris L, Cole B, Vollmer T. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Arch Neurol. 1997;54:1475-1480.
55. Rice GP, Oger J, Duquette P, et al. Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Can J Neurol Sci. 1999;26:276-282.
56. Nortvedt MW, Riise T, Myhr KM, et al. Type 1 interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. Mult Scler. 1999;5:317-322.
57. Parkin D, Jacoby A, McNamee P, et al. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry. 2000;68:144-149.
58. Vickrey BG, Hays RD, Genovese BJ, et al. Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. J Clin Epidemiol. 1997;50:557-569.
59. Arnoldus JH, Killestein J, Pfennings LE, et al. Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler. 2000;6:338-342.
60. Vermersch P, de Seze J, Delisse B, et al. Quality of life in multiple sclerosis: influence of interferon-beta1a (Avonex) treatment. Mult Scler. 2002;8:377-381.
61. Ware JE Jr, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33:AS264-AS279.
62. Zivadinov R, Zorzon M, Tommasi MA, et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci. 2003;216:113-118.
63. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996;47:129-139.
64. Simone IL, Ceccarelli A, Tortorella C, et al. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes. 2006;4:96.
65. Lily O, McFadden E, Hensor E, et al. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler. 2006;12:808-813.
66. Ford HL, Gerry E, Tennant A, et al. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil. 2001;15:247-258.